Gary A Lyons's Insider Trades & SAST Disclosures
Gary A Lyons's most recent trade in Travere Therapeutics Inc was a trade of 40,000 Common Stock done at an average price of $10.5 . Disclosure was reported to the exchange on Oct. 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gary A Lyons.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.48 per share. | 04 Oct 2024 | 40,000 | 91,000 (0%) | 0% | 10.5 | 419,200 | Common Stock |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 40,000 | 0 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 14.35 per share. | 04 Oct 2024 | 21,179 | 69,821 (0%) | 0% | 14.3 | 303,874 | Common Stock |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 15.15 per share. | 04 Oct 2024 | 18,821 | 51,000 (0%) | 0% | 15.2 | 285,227 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 11,570 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 150.43 per share. | 13 Aug 2024 | 11,570 | 119,047 (0%) | 0% | 150.4 | 1,740,450 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 13 Aug 2024 | 11,570 | 130,617 (0%) | 0% | 42.8 | 494,733 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 150.03 per share. | 16 Jul 2024 | 930 | 119,047 (0%) | 0% | 150.0 | 139,530 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 16 Jul 2024 | 930 | 119,977 (0%) | 0% | 42.8 | 39,767 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 930 | 11,570 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,982 | 2,982 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,435 | 1,435 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 119,047 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 14 May 2024 | 12,500 | 129,447 (0%) | 0% | 42.8 | 534,500 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 135.63 per share. | 14 May 2024 | 12,500 | 116,947 (0%) | 0% | 135.6 | 1,695,370 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 12,500 | 12,500 | - | - | Non-Qualified Stock Option | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 51,000 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Gary Lyons A. | Director | Sale of securities on an exchange or to another person at price $ 130.04 per share. | 22 Dec 2023 | 10,000 | 193,697 (0%) | 0% | 130.0 | 1,300,443 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary Lyons A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 01 Dec 2023 | 5,000 | 208,697 (0%) | 0% | 13.0 | 64,900 | Common Stock |
| Neurocrine Biosciences, Inc. | A. Lyons Gary | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 5,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | A. Gary Lyons | Director | Sale of securities on an exchange or to another person at price $ 116.77 per share. | 01 Dec 2023 | 5,000 | 203,697 (0%) | 0% | 116.8 | 583,837 | Common Stock |
| Rigel Pharmaceuticals | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 25,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,290 | 4,290 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 2,100 | 2,100 | - | - | Restricted Stock Unit | |
| Eledon Pharmaceuticals Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 150,437 | 150,437 | - | - | Common Stock | |
| Eledon Pharmaceuticals Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.71 per share. | 31 Oct 2022 | 15,000 | 218,697 (0%) | 0% | 12.7 | 190,650 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2022 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 114.76 per share. | 31 Oct 2022 | 15,000 | 203,697 (0%) | 0% | 114.8 | 1,721,403 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 110.54 per share. | 04 Oct 2022 | 5,000 | 203,697 (0%) | 0% | 110.5 | 552,711 | Common Stock |
| Rigel Pharmaceuticals | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 25,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.66 per share. | 25 Apr 2022 | 15,000 | 223,697 (0%) | 0% | 6.7 | 99,900 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 92.76 per share. | 25 Apr 2022 | 15,000 | 208,697 (0%) | 0% | 92.8 | 1,391,393 | Common Stock |
| Eledon Pharmaceuticals Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 105.06 per share. | 07 Oct 2021 | 5,000 | 208,697 (0%) | 0% | 105.1 | 525,294 | Common Stock |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 100.27 per share. | 10 Jun 2021 | 10,000 | 213,697 (0%) | 0% | 100.3 | 1,002,743 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 37,000 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 120.03 per share. | 25 Jan 2021 | 1,600 | 224,097 (0%) | 0% | 120.0 | 192,047 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 25 Jan 2021 | 400 | 223,697 (0%) | 0% | 120 | 48,000 | Common Stock |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.81 per share. | 15 Sep 2020 | 11,934 | 24,729 (0%) | 0% | 0.8 | 9,667 | Common Stock |
| Eledon Pharmaceuticals Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2020 | 1,167 | 1,167 | - | - | Stock Option (Right to Buy) | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.94 per share. | 31 Aug 2020 | 8,631 | 12,795 (0%) | 0% | 0.9 | 8,113 | Common Stock |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 692 | 0 | - | - | Restricted Stock Units | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2020 | 692 | 21,772 (0%) | 0% | - | Common Stock | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.94 per share. | 31 Aug 2020 | 346 | 21,426 (0%) | 0% | 0.9 | 325 | Common Stock |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2020 | 692 | 21,426 (0%) | 0% | - | Common Stock | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2020 | 692 | 692 | - | - | Restricted Stock Units | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 31 Jul 2020 | 346 | 21,080 (0%) | 0% | 0.9 | 318 | Common Stock |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 691 | 1,384 | - | - | Restricted Stock Units | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 691 | 21,080 (0%) | 0% | - | Common Stock | |
| Fresh Tracks Therapeutics Inc | Gary A. Lyons | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 30 Jun 2020 | 346 | 20,734 (0%) | 0% | 1 | 346 | Common Stock |
| Neurocrine Biosciences, Inc. | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2020 | 6,018 | 6,018 | - | - | Non-Qualified Stock Option | |
| Rigel Pharmaceuticals | Gary A. Lyons | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 9,000 | 9,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Gary A. Lyons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 3,000 | 34,000 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges